PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD₂ antibody ch14.18/CHO

References

• Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012; 18:2740-53; PMID:22589483; https://doi.org/10.1158/1078-0432.CCR-11-1939
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; https://doi.org/10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: A SIOPEN Phase 1 study. MAbs 2013; 5:801-9; PMID:23924804; https://doi.org/10.4161/mabs.25215
   PubMed Web of Science ®Google Scholar
• Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Juttner M, Ehlert K, Kietz S, Müller I, Lode HN. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncoimmunology 2016; 5:e1235108; PMID:27999754; https://doi.org/10.1080/2162402X.2016.1235108
   PubMed Web of Science ®Google Scholar
• Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 2005; 42:1311-9; PMID:15950727; https://doi.org/10.1016/j.molimm.2004.12.018
   PubMed Web of Science ®Google Scholar
• Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 2012; 3:91; PMID:22623917; https://doi.org/10.3389/fphar.2012.00091
   PubMed Web of Science ®Google Scholar
• Lode HN, Jensen C, Endres S, Pill L, Siebert N, Kietz S, et al. Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients. J clin oncol 2015; 32:5.
   Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; https://doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• van Dam LS, de Zwart VM, Meyer-Wentrup FA. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Pediatr Blood Cancer 2015; 62:190-7; PMID:25327979; https://doi.org/10.1002/pbc.25284
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016; 9:5023-39; PMID:27574444; https://doi.org/10.2147/OTT.S105862
   PubMed Web of Science ®Google Scholar
• Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 2015; 13:14; PMID:25889536; https://doi.org/10.1186/s12964-015-0093-y
   PubMed Web of Science ®Google Scholar
• Boes M, Meyer-Wentrup F. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett 2015; 361:49-56; PMID:25697485; https://doi.org/10.1016/j.canlet.2015.02.027
   PubMed Web of Science ®Google Scholar
• Dondero A, Pastorino F, Della CM, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology 2016; 5:e1064578; PMID:26942080; https://doi.org/10.1080/2162402X.2015.1064578
   PubMed Web of Science ®Google Scholar
• Chowdhury F, Dunn S, Mitchell S, Mellows T, Ashton-Key M, Gray JC. PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. OncoImmunology 2015; 4:e1029701; https://doi.org/10.1080/2162402X.2015.1029701
   Web of Science ®Google Scholar
• Siebert N, Seidel D, Eger C, Juttner M, Lode HN. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PLoS One 2014; 9:e107692; PMID:25226154; https://doi.org/10.1371/journal.pone.0107692
   PubMed Web of Science ®Google Scholar
• Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller HP, Helm C, et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother 2013; 62:999-1010; PMID:23591980; https://doi.org/10.1007/s00262-013-1413-y
   PubMed Web of Science ®Google Scholar
• Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. J Immunol Methods 2013; 398-399:51-9; PMID:24055592; https://doi.org/10.1016/j.jim.2013.09.008
   PubMed Web of Science ®Google Scholar
• Siebert N, Eger C, Seidel D, Juttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs 2016; 8:604-16; PMID:26785755; https://doi.org/10.1080/19420862.2015.1130196
   PubMed Web of Science ®Google Scholar
• Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, et al. PD-L1 Is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA Class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res 2017; PMID:28270499; https://doi.org/10.1158/1078-0432.CCR-16-2601
   PubMed Web of Science ®Google Scholar
• Kircheis R, Halanek N, Koller I, Jost W, Schuster M, Gorr G, Hajszan K, Nechansky A. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. MAbs 2012; 4:532-41; PMID:22665069; https://doi.org/10.4161/mabs.20577
   PubMed Web of Science ®Google Scholar
• Wagner LM, Adams VR. Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther 2017; 10:2097-106; PMID:28442918; https://doi.org/10.2147/OTT.S124008
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology 2016; 5:e1004983; PMID:27057424; https://doi.org/10.1080/2162402X.2015.1004983
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997; 89:1586-94; PMID:9362156; https://doi.org/10.1093/jnci/89.21.1586
   PubMedGoogle Scholar
• Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother 2015; 64:621-34; PMID:25711293; https://doi.org/10.1007/s00262-015-1669-5
   PubMed Web of Science ®Google Scholar
• Fang M, Meng Q, Guo H, Wang L, Zhao Z, Zhang L, Kuang J, Cui Y, Mai L, Zhu J. Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis. Mol Vis 2015; 21:901-10; PMID:26321864
   PubMed Web of Science ®Google Scholar